ABT-670

In this article about ABT-670 we will explore different aspects and perspectives about this broad and relevant topic in today's society. From its origin and evolution, to its implications in different areas of daily life, we will delve into a detailed analysis that will allow us to better understand the multiple dimensions that ABT-670 encompasses. Through research and reflection, we seek to shed light on aspects that are little known or debated, in order to enrich our understanding of ABT-670 and its implications in the contemporary world.

ABT-670
Identifiers
  • 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H--1'-ylmethyl)benzamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H23N3O2
Molar mass325.412 g·mol−1
3D model (JSmol)
  • 1ccccc1C(CC3)CCN3CNC(=O)c(c2)cccc2C
  • InChI=1S/C19H23N3O2/c1-15-5-4-6-17(13-15)19(23)20-14-21-11-8-16(9-12-21)18-7-2-3-10-22(18)24/h2-7,10,13,16H,8-9,11-12,14H2,1H3,(H,20,23) checkY
  • Key:PUMMPCXNEPHBNN-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

ABT-670 is a drug which acts as a potent, orally bioavailable dopamine agonist selective for the D4 subtype, which was developed as a possible treatment for erectile dysfunction,[1] although its current uses are limited to scientific research.[2]

See also

References

  1. ^ Patel MV, Kolasa T, Mortell K, Matulenko MA, Hakeem AA, Rohde JJ, et al. (December 2006). "Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H--1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction". Journal of Medicinal Chemistry. 49 (25): 7450–65. doi:10.1021/jm060662k. PMID 17149874.
  2. ^ Richards N, Wayman C, Allers KA (November 2009). "Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection". Neuroscience Letters. 465 (3): 242–7. doi:10.1016/j.neulet.2009.08.078. PMID 19733217. S2CID 27767274.